Korean PharmaBio Surges into JPMHC for Business Opportunities

South Korean pharmaceutical and bio companies are gearing up to participate in the '2024 JP Morgan Healthcare Conference' (JPMHC) in California, USA, from January 8th to the 11th. They aim to engage in partnering discussions for global corporations and technology transfer opportunities.

This year marks the 42nd edition of the JPMHC, recognized as the largest event in the pharmaceutical and bio investment industry. Anticipated attendance includes about 600 companies in pharmaceuticals, bio, and healthcare, with over 8,000 corporate and investor attendees.

Industry sources revealed on January 4th that key players such as Samsung Biologics, Celltrion, Yuhan Corporation, Hanmi Pharmaceutical, SK Biopharmaceuticals, Lotte Biopharmaceuticals, GC Cell, and BridgeBio Therapeutics will be actively participating. Moreover, several other companies are set to join the concurrent 'Biotech Showcase 2024.'

Samsung Biologics and Celltrion are slated to present at the 'Main Track' of the event. Samsung Biologics, invited by JP Morgan for the eighth consecutive year, will deliver its presentation at the core of the JPMHC, focusing on their 2023 achievements, 2024 outlook, and long-term vision under the theme 'Leap Forward, Beyond the Reach of the Past' on January 9th at the Grand Ballroom.

Celltrion plans to unveil the vision of Integrated Celltrion at this year's JPMHC Main Track. Jin-Seok Seo, co-CEO of Celltrion, is expected to present the business vision and objectives alongside Chairman Jung-Jin Seo.

Yuhan Pharmaceuticals, SK Biopharmaceuticals, Lotte Biologics, Kakao Healthcare, and others will conduct presentations focused on the Asia-Pacific and Latin America (APAC & LatAm) sessions at JPMHC.

Yuhan Pharmaceuticals will feature Yeol-Hong Kim, Head of Research and Development (R&D), as the speaker. Kim will discuss the major pipeline, including the non-small cell lung cancer treatment ‘Leclaza (active ingredient: Lazertinib).'

SK Biopharmaceuticals will introduce their achievements and long-term growth drivers for the epilepsy drug 'Xcopri (known as Cenobamate in the U.S.)' during the session, presented by CEO Dong-Hoon Lee.

Lotte Biologics, a Contract Development and Manufacturing Organization (CDMO), will showcase mid-to-long-term strategies, while Kakao Healthcare will introduce their diabetes management solution through CEO Hee Hwang.

Hanmi Pharmaceutical, known for its proprietary platform technology 'Rapid Discovery' and substantial deals, will promote its major pipeline at this year's event.

GC Cell aims to present its 'Blueprint 2.0' business strategy, focusing on in-house natural killer (NK) and CAR-NK cell therapy pipelines. Additionally, companies like SK Bioscience, GI Innovation, ABL Bio, Dx&Vx, and Mepsgen are also participating.

BridgeBio Therapeutics, participating in this JPMHC after a three-year hiatus, aims to leverage the event to engage with global pharmaceutical and bio companies, exploring opportunities for technology transfer on key R&D initiatives and seeking partnerships for new anticancer combination therapies. Additionally, companies like SK Bioscience, GI Innovation, ABL Bio, Dx&Vx, and Mepsgen are also participating in the JPMHC event.

Korean pharmaceutical and bio companies view the JPMorgan Healthcare Conference (JPMHC) as pivotal for their business development. A bio venture representative emphasized the event's significance, stating, 'JPMHC sets the stage for shaping our business direction through diverse discussions with global decision-makers.' They added, 'Major deals often emerge during JPMHC, making it a pivotal platform for business development.'